Photo Nature Travel / Shutterstock.com
2 July 2025NewsAmericasLiz Hockley

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 June 2026   A district court has thrown out one challenge over the vaccine delivery technology, while a separate appeal could affect protections available to government contractors during national emergencies.
Americas
1 June 2026   A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.
Americas
29 May 2026   A US appeals court has thrown out a jury verdict against a South Korean medical device company, ruling that Insulet waited too long to bring its trade secret misappropriation claim.